Beyond Air reports $2.3M in preliminary Q3 2026 revenue

Go back to Beyond Air reports $2.3M in preliminary Q3 2026 revenue

Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026

October 8, 2026 8:00 AM EDT

Preliminary revenue of $2.3 million represents the highest quarterly revenue reported, and approximately 30% sequential quarterly growth and 27% growth over the same period last year

Performance reflects continued adoption for first-generation LungFit PH; second-generation system remains under FDA review

Reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027

GARDEN CITY, N.Y., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve... More